Inaktiver Wert

Andere Sprachen Fennec Pharmaceuticals Inc. Nasdaq

Aktien

CA31447P1009

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:52:46 29.05.2024			% 5 Tage	% 1. Jan.
6,805 ^USD	0,00 %		0,00 %	0,00 %

15.05.	FENNEC PHARMACEUTICALS INC. : HC Wainwright bekräftigt seine Kaufempfehlung	ZM
14.05.	Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Fennec Pharmaceuticals : Corporate Presentation May 2024	15.05.
Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue	14.05.
Fennec Pharmaceuticals Brief: Company Says Has Approximately US$51 Million in Cash, Cash Equivalents, and Investment Securities	14.05.
Fennec Pharmaceuticals Brief: Achieved Q1 2024 Total Net Revenues of US$25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction	14.05.
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	14.05.
Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024	08.05.
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	23.04.
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	19.04.
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	17.04.
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	05.04.
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	03.04.
Fennec Pharmaceuticals : Corporate Presentation March 2024	31.03.
Wedbush on Fennec's Q4	21.03.
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	21.03.
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	21.03.
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	21.03.
North American Morning Briefing : Investors -2-	21.03.
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	21.03.
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update	21.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Fennec Pharmaceuticals Inc. Nasdaq

Aktien

CA31447P1009

Andere Sprachen

Filter